Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Cellectis S.A.. (11/13/17). "Press Release: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017". New York, NY.

Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 Calyxt Inc. (Nasdaq Global Market: CLXT)
  Group Cellectis (Group)
Products Product UCART123 (Cellectis)
  Product 2 UCART19 (Cellectis / Servier / Pfizer / Allogene)
Index term Index term Cellectis–SEVERAL: investment, 201706–201707 Calyxt IPO $64.4m w 7m+1.05m common shares at $8/share Cellectis retains 79.9% shareholding
Persons Person Simon, Mathieu (Cellectis 2013–201803 COO joined 201204 as SVP Cellectis Group before Pierre Fabre + Wyeth RETIRED 3/18)
  Person 2 Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)
     


   
Record changed: 2017-11-26

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px




» top